Study to Evaluate Using JSP191 With ARU-1801 as Gene Therapy

Study to Evaluate Using JSP191 With ARU-1801 as Gene Therapy

299229

Study to Evaluate Using JSP191 With ARU-1801 as Gene Therapy

A new research collaboration between Jasper Therapeutics and Aruvant Sciences will evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody, as a conditioning agent for ARU-1801, Aruvant’s experimental gene therapy for sickle cell disease (SCD). “The unique attributes of ARU-1801 enable us to bring a potentially curative one-time therapy to individuals with sickle cell disease that can be delivered in the safest way possible. By partnering with Jasper to evaluate the use of JSP191 with ARU-1801,…

You must be logged in to read/download the full post.